Search

Your search keyword '"Garcia-Closas, M."' showing total 810 results

Search Constraints

Start Over You searched for: Author "Garcia-Closas, M." Remove constraint Author: "Garcia-Closas, M."
810 results on '"Garcia-Closas, M."'

Search Results

1. FANCM missense variants and breast cancer risk

2. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2

3. Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk

4. Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot".

5. Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights.

6. FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women

7. PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in similar to 200,000 patients (vol 24, 69, 2022)

8. PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients

9. Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women

10. Breast cancer risks associated with missense variants in breast cancer susceptibility genes

11. Common variants in breast cancer risk loci predispose to distinct tumor subtypes

12. Rare germline copy number variants (CNVs) and breast cancer risk

13. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes

14. Methylation-based markers of aging and lifestyle-related factors and risk of breast cancer: a pooled analysis of four prospective studies

15. Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies

16. PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in similar to 200,000 patients

17. Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study

18. PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in similar to 200,000 patients (vol 24, 69, 2022)

19. Common variants in breast cancer risk loci predispose to distinct tumor subtypes

20. Rare germline copy number variants (CNVs) and breast cancer risk

21. Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element

22. CYP3A7*1C allele:linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers

23. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature Communications, (2021), 12, 1, (1078), 10.1038/s41467-020-20496-3).

24. Breast cancer risk factors and survival by tumor subtype: Pooled analyses from the breast cancer association consortium.

25. Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer.

26. Mendelian randomisation study of smoking exposure in relation to breast cancer risk.

27. Genetic insights into biological mechanisms governing human ovarian ageing.

28. Breast cancer risk genes - Association analysis in more than 113,000 women.

29. Erratum: Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature communications (2021) 12 1 (1078)).

30. Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element.

31. Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries.

32. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers.

33. Combined Associations of a Polygenic Risk Score and Classical Risk Factors with Breast Cancer Risk.

34. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

35. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment.

36. Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis.

37. Genetic insights into biological mechanisms governing human ovarian ageing

38. Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium

39. Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis

40. Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk

41. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

42. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers

43. Mendelian randomisation study of smoking exposure in relation to breast cancer risk

44. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (vol 12, 1078, 2021)

45. Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element

46. Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element

47. Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis

48. Mendelian randomisation study of smoking exposure in relation to breast cancer risk

49. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

50. Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program

Catalog

Books, media, physical & digital resources